The University of Chicago Medical Center is a nationally ranked academic medical center located in Hyde Park on the South Side of Chicago. It is the flagship campus for The University of Chicago Medicine system and was established in 1898.

There are 811 beds in University of Chicago Medical Center.

During the past decade, University of Chicago Medical Center conducted 456 clinical trials. In the 10-year time frame, 456 clinical trials started and 237 clinical trials were completed, i.e. on average, 52% percent of trials that started reached the finish line to date. In the past 5 years, 215 clinical trials started and 142 clinical trials were completed. i.e. 66% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Chicago Medical Center" #1 sponsor was "University of Chicago" with 152 trials, followed by "Pfizer" with 37 trials sponsored, "Bristol-Myers Squibb" with 21 trials sponsored, "Celgene" with 16 trials sponsored and "Novartis Pharmaceuticals" with 16 trials sponsored. Other sponsors include 522 different institutions and companies that sponsored additional 315 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Chicago Medical Center" #1 collaborator was "Merck Sharp & Dohme LLC" with 15 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 14 trials as a collaborator, "Bristol-Myers Squibb" with 13 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 12 trials as a collaborator and "University of Chicago" with 11 trials as a collaborator. Other collaborators include 399 different institutions and companies that were collaborators in the rest 272 trials.

According to Clinical.Site data, the most researched conditions in "University of Chicago Medical Center" are "Breast Cancer" (23 trials), "Crohn's Disease" (21 trials), "Ulcerative Colitis" (18 trials), "Multiple Myeloma" (16 trials) and "Acute Myeloid Leukemia" (14 trials). Many other conditions were trialed in "University of Chicago Medical Center" in a lesser frequency.

Most popular intervention types in "University of Chicago Medical Center" are "Drug" (510 trials), "Other" (94 trials), "Biological" (87 trials), "Device" (79 trials) and "Procedure" (35 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (111 trials), "Pembrolizumab" (19 trials), "Nivolumab" (16 trials), "Dexamethasone" (15 trials) and "Carboplatin" (12 trials). Other intervention names were less common.

The vast majority of trials in "University of Chicago Medical Center" are 717 trials for "All" genders, 37 trials for "Female" genders and 15 trials for "Male" genders.

Currently, there are 260 active trials in "University of Chicago Medical Center". 3 are not yet recruiting, 147 are recruiting, 105 are Active, not recruiting, and 5 are Enrolling by invitation. In total, there were 357 completed trials in University of Chicago Medical Center, 4 suspended trials, and 114 terminated clinical trials to date.

Out of the total trials that were conducted in University of Chicago Medical Center, 147 "Phase 1" clinical trials were conducted, 269 "Phase 2" clinical trials and 191 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 36 trials, and there were also 109 trials that are defined as “Not Applicable".

University of Chicago Medical Center has several departments that took part in Clinical trials: "University of Chicago Comprehensive Cancer Center" - 948 trials, "UC Comprehensive Cancer Center at Silver Cross" - 137 trials, "University of Chicago Comer Children's Hospital" - 85 trials, "UChicago Medicine Comprehensive Cancer Center - Saint Joseph Hospital" - 12 trials, "The University of Chicago Medical Center, CCD - Investigational Drug Service Pharmacy" - 3 trials, "University of Chicago Medical Center - Multiple Myeloma Research Consortium" - 2 trials, "University of Chicago, Division of Infectious Diseases" - 2 trials